Bongros

Bongros

hydroxyapatite compound

Manufacturer:

Daewoong
Concise Prescribing Info
Contents
Hydroxyapatite
Indications/Uses
For filling &/or augmenting intraoral/maxillofacial osseous defects in bony voids or gaps that are not intrinsic to the stability of the bone structure. Provides space for bony ingrowth & is combined w/ bone during the healing process.
Dosage/Direction for Use
Contraindications
Indications which may be subjected to excessive impacts or stresses; segmental defects; fractures of the growth plate; significant impairment proximal to the graft site; metabolic or systemic disorders that affect bone or wound healing; when stabilization of fracture is not possible; where intraoperative soft tissue coverage is not planned or possible; infected sites. Severe vascular or neurological disease. Uncontrolled diabetes. Severe degenerative bone disease. Uncooperative patients who will not or cannot follow post-op instructions, including those who abuse drugs &/or alcohol. Hypercalcemia. History of or active Pott's disease. Renal compromised patients. Pregnancy.
Special Precautions
Do not change the size of the Bongros granule. Do not lift heavy items post-op; hardware should not be removed until damage is completely healed & joint area is no longer dependent on abnormal irregular loads.
Adverse Reactions
Wound complications (eg, hematoma, site drainage, bone fracture, infection); fracture or extrusion of Bongros w/ or w/o generation of particulate debris; deformity of bone at the site; incomplete or lack of osseous ingrowth into bone void.
ATC Classification
M05B - DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION ; Used in the treatment of bone diseases.
Presentation/Packing
Form
Bongros granules 250 mg
Packing/Price
10 cc x 1's (Rp3,800,000/vial);5 cc x 1's (Rp2,000,000/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in